Esomeprazol Sandoz 40 mg Norway - Norway - Statens legemiddelverk

esomeprazol sandoz 40 mg

sandoz - københavn - esomeprazolmagnesiumtrihydrat - enterotablett - 40 mg

Esomeprazol Sandoz 20 mg Norway - Norway - Statens legemiddelverk

esomeprazol sandoz 20 mg

sandoz a/s - esomeprazolmagnesiumtrihydrat - enterotablett - 20 mg

Esomeprazol Orifarm 10 mg Norway - Norway - Statens legemiddelverk

esomeprazol orifarm 10 mg

orifarm generics a/s - esomeprazolmagnesium - enterogranulat til mikstur, suspensjon i dosepose - 10 mg

Cipramil 20 mg Norway - Norway - Statens legemiddelverk

cipramil 20 mg

orifarm as - citalopramhydrobromid - tablett, filmdrasjert - 20 mg

Cipramil 20 mg Norway - Norway - Statens legemiddelverk

cipramil 20 mg

2care4 aps - citalopramhydrobromid - tablett, filmdrasjert - 20 mg

Hippozol vet. 400 mg Norway - Norway - Statens legemiddelverk

hippozol vet. 400 mg

cp-pharma handelsgesellschaft mbh - omeprazol - enterogranulat - 400 mg

Leptanal 50 mikrog/ ml Norway - Norway - Statens legemiddelverk

leptanal 50 mikrog/ ml

piramal critical care b.v. - fentanylsitrat - injeksjonsvæske, oppløsning - 50 mikrog/ ml

Nexium Control Kesatuan Eropah - Norway - EMA (European Medicines Agency)

nexium control

glaxosmithkline dungarvan limited - esomeprazol - gastroøsofageal refluks - proton pumpen inhibitors - nexium control er indikert for kortsiktig behandling av reflukssymptomer (f.eks. halsbrann og syreoppblåsthet) hos voksne.

Ceplene Kesatuan Eropah - Norway - EMA (European Medicines Agency)

ceplene

laboratoires delbert - histamine dihydrochloride - leukemi, myeloid, akutt - immunostimulants, - ceplene maintenance therapy is indicated for adult patients with acute myeloid leukaemia in first remission concomitantly treated with interleukin-2 (il-2). effekten av ceplene er ikke fullstendig demonstrert hos pasienter eldre enn 60 år.

Inrebic Kesatuan Eropah - Norway - EMA (European Medicines Agency)

inrebic

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastiske midler - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.